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We have analyzed 143 unrelated Belgian patients with a positive diagnosis of cystic fibrosis (CF) for mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene. An initial screening for 29 CFTR mutations led to mutation identification in 89.9% of
the tested chromosomes. Subsequently an extensive analysis of the CFTR gene was performed by denaturating gradient gel electrophoresis
(DGGE) in those patients with at least one unknown mutation after preliminary screening. In addition to 10 previously reported mutations we
identified 2 new mutations 186-2A→G and E588V. A third new mutation 1671insTATCA was identified during routine screening for
ΔF508. Two mutations were detected with a higher frequency than expected: 3272-26A→G, which is the second most common mutation
after ΔF508 in our CF population with a frequency of 3.8%, and L927P (2.4%). The clinical data is presented for the mutations 186-2A→G,
E588V, 3272-26A→G and L927P. The mutation data are useful for the Belgian population to supplement the initial screening set of
mutations.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Belgian; Antwerp; Cystic fibrosis; CFTR; DGGE; Genotype–phenotype1. Introduction
Cystic fibrosis (CF) is one of the most common severe
autosomal recessive disorders among Caucasians with an
estimated incidence of 1:2500. The clinical expression of the
disease is heterogeneous but most patients with CF typically
present with chronic obstructive lung disease, elevated
electrolyte concentration in the sweat, insufficient pancreatic⁎ Corresponding author.
E-mail address: katrien.storm@ua.ac.be (K. Storm).
1 Current address: Life & Brain Center, University of Bonn, Bonn,
Germany.
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doi:10.1016/j.jcf.2006.10.013exocrine function (PI), and male infertility [1,2]. Approxi-
mately 10–15% of CF patients has pancreatic sufficiency
(PS) [3]. Since the identification of the cystic fibrosis
transmembrane conductance regulator (CFTR) gene [4,5,6],
more than 1000 CFTR mutations have been reported to the
Cystic Fibrosis Genetic Analysis Consortium [7]. The
ΔF508 mutation is the most common mutation with an
average frequency in Caucasian CF chromosomes of 66%
[7] and with a wide variation among different populations
[4]. Few mutations have a frequency between 1 and 5%.
Most mutations however are rare and occur with a frequency
of less than 1% [7].
In the present study, we report the spectrum and frequency
of CFTR mutations in Belgian CF patients from the regioned by Elsevier B.V. All rights reserved.
Table 1
Spectrum and frequencies of CFTR mutations in unrelated Belgian CF
patients (Antwerp region)
CFTR mutation Number of CF-chromosomes Frequency (%)
1 ΔF508 a 210 73.4
2 3272-26A→Gb 11 3.8
3 N1303Ka 10 3.5
4 S1251Na 7 2.4
G542Xa 7 2.4
L927P b 7 2.4
5 2789+5G→Ac 6 2.1
6 1717-1G→Aa 5 1.7
7 A455E c 3 1.0
8 2183AA→Gc 2 0.7
E60Xc 2 0.7
R334Wc 2 0.7
9 ΔI507 a 1 0.3
3659delC c 1 0.3
3849+10kb C→Tc 1 0.3
186-2A→G 1 0.3
E588Vb 1 0.3
L159S b 1 0.3
G178Rb 1 0.3
W401Xb 1 0.3
1833delT b 1 0.3
E730Xb 1 0.3
P750L b 1 0.3
Y1092Xb 1 0.3
M1137Rb 1 0.3
10 Unknown 1 0.3
Total 286 100.0
a Inno Lipa™ CFTR12 mutations.
b Mutations identified by DGGE/sequencing analysis.
c Inno Lipa™ CFTR17 mutations.
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study the clinical data is presented.
2. Materials and methods
2.1. Samples
A total of 143 unrelated Belgian CF families with at least
one affected child with a confirmed diagnosis of CF was
studied. The diagnostic criteria used were those proposed by
Rosenstein et al. [8]. Genomic DNA was extracted from
peripheral blood lymphocytes [9]. If possible DNA analysis
of the index cases was followed by analyzing the parents to
show that the mutations under study were located on separate
chromosomes.
2.2. Detection of known mutations
Twenty-nine frequent CFTR mutations were analyzed by
two DNA line probe assays based on the reverse hybridiza-
tion principle [10]. The Inno Lipa™ CFTR12 assay contains
normal and mutant probes for 12 different CFTR mutations
(ΔF508, G542X, N1303K, 1717-1G→A, W1282X, G551D,
R553X, S1251N, R560T, 3905insT, Q552X, ΔI507). The Inno
Lipa™CFTR17 assay contains normal andmutant probes for
17 other CFTR mutations (394delTT, G85E, 621+1G→T,
R117H, 1078delT, R347P, R334W, E60X, 711+5G→A,
2789+5G→A, R1162X, 3659delC, 3849+10kbC→ T,
2143delT, A455E, 2183AA→G, 2184delA) (Innogenetics).
These assays should allow identification of 87% of the
Belgian CFTR mutations.
2.3. Detection of unknown mutations
Denaturating gradient gel electrophoresis (DGGE) anal-
ysis was carried out on all coding exons of the CFTR gene
including the exon–intron boundaries, except for exon 9
which was sequenced directly. Sequences of primers, PCR
conditions, optimal gradient conditions and migration time
were kindly provided by Dr. Robert M.W. Hofstra
(Department of Medical Genetics, University of Groningen,
The Netherlands).
2.4. DNA sequencing
DNA fragments displaying aberrant electrophoretic
DGGE patterns were sequenced directly using the Big Dye
Terminator Cycle Sequencing Reaction Kit (Perkin Elmer),
and analyzed on an ABI 3100 Automated Sequencer.
2.5. Mutation nomenclature
Nucleotide numbers are derived from cDNA CFTR
sequences (GenBank accession no. NM_000492). Mutations
are named according to the numbering used in the CFTR
Mutation Database (http://www.genet.sickkids.on.ca/cftr/).3. Results and discussion
3.1. Molecular analysis
In this study, we first analyzed 29 CFTR mutations in 286
unrelated CF chromosomes from Belgian patients. The
ΔF508 mutation was found in 73.4% of the tested
chromosomes. Twelve other mutations were found and
accounted for another 16.5% of tested chromosomes.
Sixteen of the 29 tested mutations were not present in our
patient group. In total, we could characterize 89.9% (257/
286) of the CF alleles. In those patients with at least one
unknown mutation DGGE analysis of the ‘negative’ CF
chromosomes, followed by sequencing analysis of the
aberrant fragments, revealed the presence of 12 different
CFTR mutations (28/29 CF alleles). In one patient only one
mutation (ΔF508) could be identified. This male patient
(now 35 years old) presented at the age of 27 a sweat chloride
concentration of 100 mEq/l, mild lung disease and pancreatic
insufficiency. Two younger sibs also affected with cystic
fibrosis died at a much younger age. From the 12 different
mutations identified by DGGE 10 mutations are reported
before and 2 mutations (186-2A→G and E588V) are new.
(Table 1) A third new mutation 1671insTATCA causing a
frameshift in exon 10 and creating a premature stop of
Table 2
Frequency of the mutations 3272-26A→G and L927P for different parts of
Belgium and other countries
Country/Region Frequency 3272-26A→G (%) Reference
Belgium/Antwerp 3.8 This study
Belgium/Brussels 1.7 W. Lissens, pers.
comm.
Belgium/Ghent 0.9 L. Messiaen, pers.
comm.
Belgium/Leuven 1.0 [14]
The Netherlands 0.9 H. Scheffer, pers.
comm.
France 0.5 [15–17]
Germany 0.9 [18]
Greece 0.8 [19,20]
Spain 0.5 [21]
Canada (Toronto) 0.5 [22]
Portugal 2.0 [11]
South Africa
(white population)
4.2 [23]
Frequency L927P (%)
Belgium/Antwerp 2.4 This study
Belgium/Brussels 0.7 W. Lissens, pers.
comm.
Belgium/Gent 0.3 L. Messiaen, pers.
comm.
The Netherlands 0.5 [13]
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routine screening forΔF508 (heteroduplex analysis). Two of
the 10 previously reported mutations were detected with a
higher frequency than expected: the mutation 3272-
26A→G is the second most common CFTR mutation in
the Antwerp patient population (after ΔF508), with a
frequency of 3.8%. L927P (together with G542X and
S1251N) is the fourth most common CFTR mutation, with
a frequency of 2.4%. (Table 2) Remarkably, the incidence of
3272-26A→G differs between different parts of Belgium
(from about 1 to 3.8%) and seems to be the highest for
Antwerp. More, the incidence of 3272-26A→G in
Antwerp is comparable with that of the white population in
South Africa. This can probably partially be explained by
historical bonds between South Africa and the Antwerp
region with migration of inhabitants of Antwerp to SouthTable 3
Clinical phenotypes of patients compound heterozygous for L927P and a second
Genotype (L927P/any) Patient 1 Patient
Second mutation ΔF508 ΔF508
Sex Male Female
Age at diagnosis 1 month (meconium ileus) ?
Current age 1.5 year 9 year
Pancreatic insufficiency Yes Yes
FEV1 (% predicted) / 88.1
Pseudomonas aeruginosa colonization No No
Sweat Na (mEq/l) ? 142
Sweat Cl (mEq/l) 118 160Africa (via the Netherlands) and with direct trade routes
between South Africa and the port of Antwerp. Also the
incidence of the mutation L927P differs between different
parts of Belgium and seems to be the highest for Antwerp
(with frequencies from 0.3 up to 2.4%). (Table 2) These
numbers are especially useful for carrier screening in the
Belgian population, specifically for the population from the
Antwerp region.
3.2. Genotype–phenotype studies
3.2.1. Frequent mutations
3.2.1.1. 3272-26A→G. It was previously shown that the
3272-26A→G mutation leads to the creation of an
alternative acceptor splice site competing with the normal
one during RNA processing and resulting in the occurrence
of an alternatively spliced mRNA with 25 extra nucleotides
from intron 17a and a premature stop codon soon thereafter
[11]. Amaral et al. [12] reported the clinical phenotypes of 60
CF patients with the mutation 3272-26A→G and found that
these were significantly milder than those of ΔF508 ho-
mozygotes. In this study, the mutation is found in 11/143 CF
patients. In 10 patients ΔF508 is the second mutation. One
patient is compound heterozygous for 3272-26A→G and
1717-1G→A. The clinical phenotypes of our patients are
milder than those of ΔF508 homozygotes, and are in
concordance with the phenotypes described by Amaral et al.
[12].
3.2.1.2. L927P. The mutation L927P is caused by the
transition of a T to C at nucleotide position 2912 in exon 15,
and changes a leucine to a proline at position 927 of the
protein. The L927P is described before by Hermans et al. [13]
in 3 families (5 patients). They concluded that most likely
L927P can be classified as a severe CF mutation comparable
with ΔF508. We found L927P in 7 CF patients: four patients
have ΔF508 as the second mutation, one patient 1717-
1G→A, another patient S1251N, and a last patient 2789+
5G→A. The clinical phenotypes of these patients are given
in Table 3. For the patient with 2789+5G→A extended
clinical information was missing. The patients described in
Table 3 presented more gastro-intestinal problems andmutation
2 Patient 3 Patient 4 Patient 5 Patient 6
ΔF508 ΔF508 1717-1GNA S1251N
Male Female Female Female
b1 year b1 year Neonatal (meconium ileus) ?
20 year 5 year 10 year 35 year
Yes Yes Yes Yes
86.7 72.6 80.4 70
No Yes No Yes
? 88 89 ?
? 105 106 ?
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and stagnation of weight. 80% of them were also pancreatic
insufficient. Lung problems and spirometry values were
similar to the classic ΔF508. Children with L927P were
mostly diagnosed in the neonatal period. From this, we
conclude that patients with L927P show clinical features
comparable to patients homozygous for ΔF508.
3.2.2. New mutations
3.2.2.1. 186-2A→G. The mutation 186-2A→G constitu-
tes a splicing defect in intron 1. The nucleotide substitution
ANG at position 186-2 most probably creates an alternative
cryptic acceptor splice site that competes with the normal
acceptor splice site during RNA processing reducing
splicing from the correct site. mRNA sudies should be
performed to confirm this. The mutation is found in a male
patient displaying a phenotype with a high sweat chloride
concentration (102 mEq/l), pancreatic insufficiency and
development of nasal polyps. The patient is compound
heterozygous for ΔF508 and 186-2A→G.
3.2.2.2. E588V. Themissensemutation E588Vis caused by
a transversion of A to T at nucleotide 1895 in exon 12 of the
CFTR gene leading to a change of glutamic acid to valine at
amino acid position 588. It is found in a male patient with
obstructive lung disease, pancreatic insufficiency, and
pseudomonas colonization. The patient is compound hetero-
zygous for ΔF508 and E588V. Arguments for a pathogenic
character of E588V are (1) the mutation was not detected in
96 control chromosomes, (2) a relative large charged polar
amino acid is substituted by a small apolar amino acid. (3) the
glutamic acid at position 588 is conserved in several species.
In conclusion, extensive mutation analysis of the 27 exons
and flanking intron sequences of the CFTR gene by DGGE
analysis in 143 Belgian CF patients from the Antwerp region
led to the identification of almost 100% of the disease-
causing mutations. In this study, the detection efficiency of
DGGE seems to be high only because CF patients with
already one identified mutation after preliminary screening
were included. In one patient no second CFmutation could be
identified, most probably due to incomplete sensitivity of
DGGE. Twenty-five different mutations were identified
including two new CFTR mutations 186-2A→G and
E588V. Two known mutations 3272-26A→G and L927P
were shown to occur with a higher frequency in Antwerp
compared to other Belgian regions. We conclude that 3272-
26ANG is a milder mutation than ΔF508, as reported before
by Amaral et al. [12], and that L927P can be classified as a
severe mutation comparable with ΔF508.
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